Accepted Manuscript

Loss of Infliximab Into Feces is Associated With Lack of Response to Therapy in Patients with Severe Ulcerative Colitis

J.F. Brandse, MD, G.R. van den Brink, prof. MD, M.E. Wildenberg, Phd, D. van der Kleij, Phd, T. Rispens, Phd, J.M. Jansen, MD, prof. R.A. Mathôt, C.Y. Ponsioen, MD, Phd, M. Löwenberg, MD, Phd, G.R.A.M. D'Haens, prof. MD

A Controlled Trial of Gluten-Free Diet I Prince State Controlled Trial of Gluten-Free Diet I Prince State Controlled Trial of Gluten-Free State Controlled Trial of Gluten-Free Diet I Prince State Controlled Trial of Gl

PII: S0016-5085(15)00572-7 DOI: 10.1053/j.gastro.2015.04.016

Reference: YGAST 59725

To appear in: Gastroenterology
Accepted Date: 21 April 2015

Please cite this article as: Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, Mathôt RA, Ponsioen CY, Löwenberg M, D'Haens GRAM, Loss of Infliximab Into Feces is Associated With Lack of Response to Therapy in Patients with Severe Ulcerative Colitis, *Gastroenterology* (2015), doi: 10.1053/j.gastro.2015.04.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in Gastroenterology are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.

ACCEPTED MANUSCRIPT

Loss of Infliximab Into Feces is Associated With Lack of Response to Therapy in Patients with Severe Ulcerative Colitis

J.F. Brandse MD^{1,2}, G.R. van den Brink prof. MD^{1,2}, M.E. Wildenberg Phd², D. van der Kleij Phd³, T Rispens Phd⁴, J.M. Jansen MD⁵, prof. R.A. Mathôt⁶, C.Y. Ponsioen MD, Phd¹, M. Löwenberg MD, Phd¹, G.R.A.M. D'Haens prof. MD¹

Grant support

This investigator-initiated study did not receive any specific funding.

Abbreviations used in this paper:

TNF, tumour necrosis factor; IBD, inflammatory bowel disease; CD, crohn's disease; UC, ulcerative colitis; SCCAI, simple clinical colitis activity index; IQR, interquartile range; Hb, hemoglobin, CRP, C-reactive protein, IFX, infliximab.

Corresponding author: Prof. Dr. Geert D`Haens, Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands, Phone: +31 2056 66690, Fax: +31 2056 69285, E-mail: g.dhaens@amc.uva.nl

Disclosures

JB: lecture fees from MSD, Takeda, GB: has received consulting fees from Abbott laboratories and lecture fees from Abbott laboratories, Merck Sharp & Dohme and Ferring Pharmaceuticals. He has received research grants from Abbott laboratories, Crucell and Ferring Pharmaceuticals. MW: lecture fees from Ferring Pharmaceuticals. DK: No conflicts of interest, The Biologicals Laboratory of Sanquin Diagnostic Services, with Desiree van der Kleij as Head of this Laboratory, performs assays for biological levels and anti-drug antibodies for many pharmaceutical industries and hospitals TR: received honoraria for lectures from Pfizer and AbbVie. JJ: has served as a speaker for

¹Department of Gastroenterology&Hepatology, AMC, Amsterdam, the Netherlands

²Tytgat Institute for Liver and Intestinal Research, Amsterdam, the Netherlands

³Biologicals Laboratory, Sanquin Laboratory, Amsterdam, the Netherlands

⁴Sanquin Research, Sanquin Laboratory, Amsterdam, the Netherlands

⁵Department of Gastroenterology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands

⁶Department of Hospital Pharmacy, AMC, Amsterdam, the Netherlands

Download English Version:

https://daneshyari.com/en/article/6093334

Download Persian Version:

https://daneshyari.com/article/6093334

<u>Daneshyari.com</u>